| Objective:To systematically analyze the clinical efficacy and safety of tocilizumab in the treatment of systemic juvenile idiopathic arthritis.Methods:We searched PubMed,Web of Science,CBM,Wanfang and CNKI databases for randomized controlled trials of tobuzumab in the treatment of systemic juvenile idiopathic arthritis published before December2020.The keywords were " tocilizumab","systemic juvenile idiopathic arthritis","treatment","trial".The subjects were divided into experimental group and control group.The experimental group was treated with tocilizumab combined with traditional medicine,and the control group was treated with traditional medicine.The literature was screened according to the inclusion and exclusion criteria,and the quality of the included literature was evaluated.Rev Man 5.3 was used for heterogeneity test,and fixed or random effect model was used to combine OR value,P value and 95%CI according to the results of heterogeneity test.Stata 16.0 software was used for bias analysis.Results:A total of 684 patients were included in 10 literatures,including387 patients in the experimental group and 297 patients in the control group.The results of Meta analysis showed that the ACR30 and 50 improvement rates of tocilizumab in the treatment of systemic juvenile idiopathic arthritis were significantly better than those in the control group,and the OR values of ACR30 and ACR50 in the experimental group were higher than those in the control group after 3 months of treatment,but there was no significant difference in the adverse reactions between the two groups(P > 0.05).Conclusions:Tocilizumab is effective in the treatment of systemic juvenile idiopathic arthritis,the short-term effect is obvious.Tocilizumab is safe in the treatment of systemic juvenile idiopathic arthritis.The number of this study is limited,it is still necessary to expand experimental and clinical studies,increase the sample size,and look forward to stronger evidence to clarify its correlation. |
PDF Full Text Request